Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 12, 2002. The report details specific corporate actions regarding share repurchases and updates on directors' interests in company shares during November 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share transaction data:
- Share Repurchase (Nov 8): 790,000 ordinary shares purchased for cancellation at 1263.06p per share.
- Share Repurchase (Nov 11): 800,000 ordinary shares purchased for cancellation at 1226.31p per share.
- Trust Transactions: The SmithKline Beecham Employee Benefit Trust sold 1,747 shares at £12.55 per share on behalf of a participant.
- ADR Movement: The GlaxoSmithKline US Retirement Savings Plan held 18,181,430 Ordinary Share ADRs (decreased from 18,183,090) at an average price of $39.75.
Material Changes
The filing reports a reduction in the number of outstanding shares due to the cancellation of 1,590,000 shares purchased on November 8 and November 11. Additionally, there were minor adjustments in the holdings of employee benefit trusts and ADRs due to fund movements and plan participant transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The share repurchases were executed in accordance with authority granted by shareholders at the Annual General Meeting on May 20, 2002.
Key Facts for Investor Verification
- Verify the total number of shares remaining under the repurchase authority granted on May 20, 2002.
- Confirm the impact of the 1,590,000 share cancellations on the company's total share count and earnings per share.
- Review the specific terms of the SmithKline Beecham Employee Benefit Trust and US Retirement Savings Plan to understand the nature of the reported director interests.